A Phase 1 interventional study of Autologous bone marrow mononuclear cell transplantation in Cerebrovascular Accident, sponsored by Neurogen Brain and Spine Institute. Withdrawn at 1 site in India. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-10-25.
Sponsored by Neurogen Brain and Spine Institute · Phase 1, Interventional, and Treatment
The purpose of this study was to study the safety and effect of stem cell therapy on the functional recovery in patients with chronic stroke.
7,286 studies on the registry are indexed under Stroke; 2,007 are open to participants now.
Browse Stroke studies →Neurogen Brain and Spine Institute is the lead sponsor of 16 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
autologous bone marrow mononuclear cell transplantation
Biological: Autologous bone marrow mononuclear cell transplantation
bone marrow derived mononuclear cells are administered intrathecally in chronic stroke patients
Functional Independence Measure
Time frame: 6 months
This study is withdrawn, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neurogen Brain and Spine Institute